



Astec LifeSciences Ltd.

Dated: 12th August, 2013

To,
The Department of Corporate Services
National Stock Exchange Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra, Mumbai-400051

Ref: "ASTEC"

Sub: Outcome of Board Meeting

Dear Sir,

This is to inform you that the Board of Directors at their meeting held on 12th August, 2013 considered the following:


- 1) Approved the Consolidated and Standalone Unaudited Financial Results for the quarter ended 30.06.2013. (enclosed herewith)
- 2) Due to resignation of M/s P. M. Kathariya & Co., Chartered Accountants as the Statutory Auditor of the Company and as the Company is already in process of appointing M/s Shah & Kathariya as new Auditor of the Company till the conclusion of next year's Annual General Meeting, the same is subject to shareholders to accord their approval for the appointment of new auditor. Therefore, Company will submit the Limited Review Report certified by the new Auditor for the quarter ended 30.06.2013 as soon as the Appointment of New Auditor will be in place.

Kindly consider and please take the same on your records.

Thanking you,

Yours Sincerely,

FOR ASTEC LIFESCIENCES LIMITED


Tejal Jariwala

Company Secretary & Compliance Officer
Encl- A/a



Head Office :
Elite Square, 7th Floor,
274, Perin Nariman Street,
Fort, Mumbai - 400001. India
Phone: +91-22- 2261 8212/ 2261 8504
Fax : +91-22- 2261 8289
E-mail : ah@astecls.com
Website : www.astecls.com



Unaudited Financial Results for the quarter ended 30 June, 2013

PART I		STANDALONE				CONSOLIDATED			
		Rs. In Lacs (Except for per share data)							
Sr. No	Particulars	Quarter Ended			Year Ended	Quarter Ended			Year Ended
		6/30/2013	6/30/2012	3/31/2013	3/31/2013	6/30/2013	6/30/2012	3/31/2013	3/31/2013
		(Unaudited)	(Unaudited)	(Audited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	Income from Operations								
	a) Net Sales / Income from operations (Net of Excise Duty)	4,164.25	3,153.26	5,695.28	16,527.07	4,226.15	3,215.16	5,721.18	17,448.10
	b) Other Operating Income	5.93	16.42	1.11	38.68	9.13	19.62	1.11	25.36
	Total Income from Operations (net)	4,170.18	3,169.68	5,696.39	16,565.75	4,235.28	3,234.78	5,722.29	17,473.46
2	Expenses								
	a) Cost of materials consumed	2,926.65	1,367.58	4,023.18	11,802.29	3,124.34	1,565.27	4,028.66	11,969.84
	b) Purchase of stock in trade	-	495.21	-	-	-	495.21	-	-
	c) Changes in inventories of finished goods and work in progress	-282.45	50.53	360.66	312.42	-456.90	-123.92	285.28	312.41
	d) Employee benefits expenses	216.21	159.87	247.22	829.46	253.37	197.03	247.22	909.86
	e) Depreciation and amortisation expenses	354.17	233.63	316.06	1,173.21	355.37	234.83	326.50	1,187.42
	f) Other expenditure	453.91	319.57	252.07	559.51	489.55	355.21	301.35	1,354.68
	Total Expenses	3,668.50	2,626.40	5,199.19	14,676.89	3,765.74	2,723.64	5,189.01	15,734.21
3	Profit/ (Loss) from operations before other income, Finance Cost and Exceptional Items (1-2)	501.68	543.29	497.20	1,888.86	469.54	511.15	533.28	1,739.25
4	Other Income	16.91	46.93	12.35	(85.26)	16.91	46.93	12.35	105.72
5	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	518.59	590.21	509.55	1,803.60	486.45	558.07	545.63	1,844.97
6	Finance Costs	157.76	189.70	158.91	703.22	181.74	213.68	123.99	748.49
6A	Foreign Exchange Fluctuation (Profit) / Loss	66.93	260.93	(41.18)	130.88	66.93	260.93	(41.18)	130.87
7	Profit after finance costs but before Exceptional Items (5-6-6A)	293.90	139.58	391.82	969.50	237.78	83.46	462.82	965.61
8	Exceptional Items (Includes adjustment relating to previous year)	31.73	2.87	73.22	94.92	31.73	2.87	73.24	94.93
9	Profit / (Loss) from ordinary activities before tax (7-8)	262.17	136.71	318.60	874.57	206.05	80.59	389.58	870.69
10	Tax Expense	59.44	61.20	95.60	280.12	59.52	61.28	96.00	279.40
11	Net Profit Profit / (Loss) from ordinary activities after tax (9-10)	202.73	75.51	223.00	594.45	146.53	19.31	293.58	591.29
12	Extra ordinary Items	-	-	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 - 12)	202.73	75.51	223.00	594.45	146.53	19.31	293.58	591.29
14	Share of Profit / (Loss) of associates								
15	Minority Interest	-	-	-	-	0.04	0.15	(5.84)	(4.97)
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (Loss) of associates (13-14-15)	202.73	75.51	223.00	594.45	146.49	19.16	299.42	596.26
17	Paid-up equity share capital (Face Value Rs.10/-)	1,804.41	1,692.91	1,804.41	1,804.41	1,804.41	1,692.91	1,804.41	1,804.41
18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	9,054.84	8,222.86	9,054.84	8,852.11	8,875.46	8,222.86	8,728.97	8,728.97
19	Earnings per share - Basic (Not Annualised)	1.12	0.45	1.30	3.45	1.12	0.11	1.74	3.45
20	Earnings per share - Diluted (Not Annualised)	1.12	0.45	1.29	3.43	1.12	0.11	1.73	3.43



PART II									
A	PARTICULARS OF SHAREHOLDING								
1	Public shareholding								
	- No of shares	7,772,150	7,497,150	7,772,150	7,772,150	7,772,150	7,497,150	7,772,150	7,772,150
	- Percentage of shareholding	43.07%	44.29%	43.07%	43.07%	43.07%	44.29%	43.07%	43.07%
2	Promoters and promoter group shareholding								
	a) Pledged / Encumbered								
	- No of shares								
	- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	- Percentage of shares (as a % of the total share capital of the company)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	b) Non-encumbered								
	- No of shares	10,271,980	9,431,980	10,271,980	10,271,980	10,271,980	9,431,980	10,271,980	10,271,980
	- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	56.93%	55.71%	56.93%	56.93%	56.93%	55.71%	56.93%	56.93%

PARTICULARS									
B	INVESTOR COMPLAINTS								
	Pending at the beginning of the quarter		1						
	Received during the quarter	1	3						
	Disposed of during the quarter	1	3						
	Remaining unresolved at the end of the quarter		1						

- The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting on 12.08.2013
- The company has only one reportable segment i.e. Agrochemicals & Pharma Intermediates.
- The Company is not submitting the Limited Review Report for the quarter ended 30th June, 2013 due to resignation of the Statutory Auditor of the Company. The Company is in the process of appointment formalities of the new Statutory Auditor and hence, Limited Review Report would be submitted after the completion of concerned formalities. The process for the appointment has already been intimated to the concerned stock exchanges.
- Above Financial Results includes financials results of M/s Behram Chemicals Pvt. Ltd. (65.63% subsidiary), Astec Europe Spri (50.10% subsidiary) and Astec CropCare Pvt Ltd (100% Subsidiary of Astec). Comercializadora Agricola Agrostrachem Cia Ltda at Columbia (100% Subsidiary of Astec)
- Figures of the previous period have been regrouped/rearranged, wherever necessary.
- key standalone financial information of the company is given below :-

Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Year ended
	6/30/2013	6/30/2012	3/31/2013	3/31/2013
	(Un audited)	(Un audited)	(Audited)	(Audited)
Net Sales / Income from operations (Net of Excise Duty)	4,164.25	3,153.26	5,695.28	16,527.07
Other Operating Income	5.93	16.42	1.11	38.68
Profit / (Loss) from ordinary activities before tax	262.17	136.71	318.60	874.57
Net Profit Profit / (Loss) from ordinary activities after tax	202.73	75.51	223.00	594.45
Earnings per share - Basic	1.12	0.45	1.30	3.45
Earnings per share - Diluted	1.12	0.45	1.29	3.43

For Astec LifeSciences Limited



(Ashok V Hiremath)

Chairman & Managing Director

Mumbai, August 12, 2013

